Mariano Barbacid

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Mariano Barbacid
Mariano Barbacid 2012.jpg
Born
Mariano Barbacid Montalbán

(1949-10-04) 4 October 1949 (age 69)
Madrid, Spain
NationalitySpanish
EducationBiochemist
Alma materUniversidad Complutense de Madrid
OccupationCancer researcher
Known forIsolating the first oncogene

Mariano Barbacid Montalbán (born 4 October 1949 in Madrid)[1] is a Spanish molecular biochemist who discovered the first oncogene. His discovery was published in the prestigious journal Nature in 1982 in an article titled "A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder-carcinoma oncogene".[2] He spent the following months extending his research, eventually discovering that such oncogene was the mutation of an allele of the Ras subfamily, as well as its activation mechanism.

In 2003 he proved that the enzyme CDK2, until then believed to be indispensable in cellular division, was not necessary in order for DNA replication to take place.

He completed his higher education in the Universidad Complutense de Madrid, where he studied chemical sciences, and in the United States, where he started as an intern; years later he was appointed director of the National Cancer Institute. He then moved back to his native Spain to lead the newly created CNIO (Centro Nacional de Investigaciones Oncológicas).

His research has been published in journals such as Nature and Nature genetics. Among his most cited research are:

  • «A point mutation is responsible for the acquisition of transforming properties by the T24 Human Bladder-Carcinoma Oncogene.» (1982).[2]
  • «Direct mutagenesis of HA-RAS-1 oncogenes by N-Nitroso-N-Methylurea during initiation of mammary carcinogenesis in rats.» (1985).[3]
  • "Ras genes." (1987).[4]
  • "The TRK proto-oncogene encodes a receptor for nerve growth-factor." (1991).[5]
  • "trkC, a new member of the trk family of tyrosine protein-kinases, is a receptor for neutotrophin-3." (1991).[6]
  • "Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors." (2000).[7]
  • "Toll-like Receptor-4 (TLR4) Down-regulates MicroRNA-107, Increasing Macrophage Adhesion via Cyclin-dependent Kinase 6." (2011)[8]

His scientific career has been awarded with prizes such as the Distinguished Young Scientist Award (1983), the King Juan Carlos I Science award (1984), the Rhodes Memorial award (1985) and the Charles Rodolphe Brupbacher (2005). His effort has also been acknowledged with the Great Cross of the Order of 2 May (2011).

Awards[edit]

  • King Juan Carlos I Award (Spain, 1984)
  • Rhodes Memorial Award (USA, 1985)
  • Joseph Steiner Award (Switzerland, 1988)
  • IPSEN Prize in neuronal plasticity (Austria, 1994)
  • Charles Rodolphe Brupbacher Cancer Prize (Switzerland, 2005)
  • International Agency for Research on Cancer Medal of Honor (France, 2007)

References[edit]

  1. ^ Javier Sampedro (29 September 2009). El País (ed.). "Barbacid deja la dirección del CNIO para centrarse en la investigación". El científico ya expresó su intención de abandonar el cargo tras la puesta en marcha del centro oncológico (in Spanish). Retrieved 29 September 2009.
  2. ^ a b Reddy EP, Reynolds RK, Santos E, Barbacid M. «A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene.» Nature 1982 Nov 11; 300 (5888): 149–52.
  3. ^ Zarbl H, Sukumar S, Arthur AV, Martin-Zanca D, Barbacid M. «Direct mutagenesis of HA-RAS-1 oncogenes by N-Nitroso-N-Methylurea during initiation of mammary carcinogenesis in rat.» Nature 1985 May 30 – Jun 5; 315 (6018): 382–5.
  4. ^ Barbacid M. «Ras genes.» Annu Rev Biochem 1987; 56: 779–827.
  5. ^ Klein R, Jing SQ, Nanduri V, O'Rourke E, Barbacid M. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell 1991 Apr 5; 65(1): 189–97.
  6. ^ Lamballe F, Klein R, Barbacid M. «trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3.» Cell 1991 Sep 6; 66 (5): 967–79.
  7. ^ Malumbres M, Ortega S, Barbacid M. «Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors.» Biol Chem 2000 Sep–Oct; 381 (9–10): 827–38.
  8. ^ Hennessy EJ, Sheedy FJ, Santamaria D, Barbacid M, O'Neill LA. «Toll-like Receptor-4 (TLR4) Down-regulates MicroRNA-107, Increasing Macrophage Adhesion via Cyclin-dependent Kinase 6.» J Biol Chem 2011 Jul 22; 286 (29): 25531-9.